{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:26:05Z","timestamp":1788276365699,"version":"build-2803163510"},"reference-count":19,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":16,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This post\u2010marketing surveillance study evaluated the real\u2010world safety and effectiveness of cabozantinib in Japanese patients with advanced renal cell carcinoma (aRCC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, observational study enrolled patients with histologically or cytologically confirmed aRCC across 102 sites in Japan. Patients received cabozantinib as monotherapy or in combination with nivolumab according to approved label regimens and were monitored for 26\u2009weeks. The primary outcome was the incidence of adverse drug reactions (ADRs) related to hepatic failure\/dysfunction and pancreatitis. Secondary outcomes included grade 3 or higher ADRs, treatment discontinuation due to ADRs, and investigator\u2010assessed objective response rate (ORR) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 388 enrolled patients, 385 were included in the analysis (median age, 71.0\u2009years; 70.1% men). Patients receiving monotherapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009322) and those receiving combination therapy (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200963) reported ADRs related to hepatic failure\/dysfunction (16.15% and 25.40%), pancreatitis\u2010related ADRs (2.80% and 4.76%), grade 3 or higher ADRs (24.84% and 38.10%), and ADRs leading to treatment discontinuation (13.98% and 30.16%), respectively. The most common grade 3 or higher ADRs were hypertension (3.73%), reduced appetite (3.11%), and hand\u2010foot syndrome (3.11%) in the monotherapy group, and diarrhea (4.76%) in the combination therapy group. The ORR was 32.9% for patients receiving monotherapy and 41.3% for those receiving\u00a0combination therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cabozantinib, as monotherapy or in combination with nivolumab, demonstrated safety and effectiveness in Japanese patients with aRCC in real\u2010world settings, consistent with previous literature. No new safety concerns were identified. These findings support the use of cabozantinib\u2010based regimens in Japanese clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trail Registration<\/jats:title>\n                    <jats:p>Japan Registry of Clinical Trials (JRCT), registration number: jRCT2031210003.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/iju.70549","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:18:30Z","timestamp":1784272710000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Post\u2010Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma"],"prefix":"10.1111","volume":"33","author":[{"given":"Hiro\u2010omi","family":"Kanayama","sequence":"first","affiliation":[{"name":"Department of Urology Kawashima Hospital  Tokushima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Statistical &amp; Quantitative Sciences, R&amp;D Data &amp; Quantitative Sciences Takeda Pharmaceutical Co. Ltd.  Osaka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Osaka","sequence":"additional","affiliation":[{"name":"Japan Medical Affairs, Japan Oncology Business Unit Takeda Pharmaceutical Co. Ltd.  Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3312-9930","authenticated-orcid":false,"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medical Sciences Kyushu University  Fukuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0264"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510016"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30107-3"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.14329"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026982"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102333"},{"key":"e_1_2_12_8_1","unstructured":"Takeda Pharmaceutical Co. Ltd \u201c\u30ab\u30dc\u30e1\u30c6\u30a3\u30af\u30b9\u932020mg\u30fb60mg [Japanese] \u201d(2026) https:\/\/www.takedamed.com\/medicine\/cabometyx\u2010rcc."},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-019-03935-x"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.4158\/EP161259.OR"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.7398"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_100013"},{"key":"e_1_2_12_13_1","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases \u201cLiverTox: Clinical and Research Information on Drug\u2010Induced Liver Injury. CABOZANTINIB \u201d(2012) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548279\/."},{"key":"e_1_2_12_14_1","unstructured":"National Institute of Diabetes and Digestive and Kidney Diseases \u201cLiverTox: Clinical and Research Information on Drug\u2010Induced Liver Injury. NIVOLUMAB \u201d(2025) https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548206\/."},{"key":"e_1_2_12_15_1","unstructured":"Takeda Pharmaceutical Co. Ltd \u201cWritten Communication Interview Form 10th Edition \u201d(2024)."},{"key":"e_1_2_12_16_1","unstructured":"Pharmaceuticals and Medical Devices Agency (PMDA) \u201cPackage Insert of Cabometyx Tablets 20 mg and 60 mg [Japanese] \u201d(2024) https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/400256_4291064F1020_1_07."},{"key":"e_1_2_12_17_1","unstructured":"Takeda Pharmaceutical Co. Ltd \u201cCommon Technical Document \u201d(2023)."},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102792"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOU.0000000000000197"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01944"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70549","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/iju.70549","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.70549","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T12:31:49Z","timestamp":1785328309000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.70549"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1111\/iju.70549"],"URL":"https:\/\/doi.org\/10.1111\/iju.70549","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-02-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70549"}}